Mark J. Ingerman
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
- Clinical Biochemistry top 5%
- Bacterial Identification and Susceptibility Testing
Papers in
-
- Antibiotics Pharmacokinetics and Efficacy 5
- Drug-Induced Hepatotoxicity and Protection 3
-
- Antimicrobial Resistance in Staphylococcus 4
- Co-authors
- Jerome Santoro (6 shared papers)Matthew E. Levison (3 shared papers)P. G. Pitsakis (2 shared papers)Elías Abrutyn (2 shared papers)Lawrence L. Livornese (3 shared papers)Robert L. Benz (3 shared papers)Alexander F. Rosenberg (1 shared paper)Audrey Wanger (1 shared paper)
- Journals
- Infectious Disease Clinics of North America (4 papers)The Journal of Infectious Diseases (2 papers)Antimicrobial Agents and Chemotherapy (1 paper)PubMed (3 papers)
- Partner nations
- United StatesCanada
In The Last Decade
Mark J. Ingerman
10 papers receiving 359 citations
Peers
Comparison fields: 5 of 66
- Molecular Medicine 122
- Clinical Biochemistry 103
- Applied Microbiology and Biotechnology 23
- Infectious Diseases 189
- Pharmacology 160
Countries citing papers authored by Mark J. Ingerman
This map shows the geographic impact of Mark J. Ingerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Ingerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Ingerman more than expected).
Fields of papers citing papers by Mark J. Ingerman
This network shows the impact of papers produced by Mark J. Ingerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Ingerman. The network helps show where Mark J. Ingerman may publish in the future.
Co-authors
The 16 scholars most cited alongside Mark J. Ingerman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1986 | 94 | |
| 2 | 1987 | 62 | |
| 3 | 1986 | 53 | |
| 4 | Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. | 1987 | 53 |
| 5 | 2000 | 38 | |
| 6 | Vancomycin. A new old agent. | 1989 | 31 |
| 7 | 1989 | 28 | |
| 8 | 1995 | 15 | |
| 9 | 2009 | 11 | |
| 10 | 2001 | 8 |
About Mark J. Ingerman
Mark J. Ingerman is a scholar working on Pharmacology, Infectious Diseases, Clinical Biochemistry, Pharmacology and Emergency Medicine, having authored 10 papers that have together received 393 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Antimicrobial Resistance in Staphylococcus (4 papers), Poisoning and overdose treatments (3 papers), Bacterial Identification and Susceptibility Testing (3 papers), Drug-Induced Hepatotoxicity and Protection (3 papers), Antibiotic Resistance in Bacteria (2 papers), Infectious Diseases and Tuberculosis (1 paper) and Osteomyelitis and Bone Disorders Research (1 paper). The work is most often cited by research in Molecular Medicine (122 citations), Clinical Biochemistry (103 citations), Applied Microbiology and Biotechnology (23 citations), Infectious Diseases (189 citations) and Pharmacology (160 citations). Mark J. Ingerman has collaborated with scholars based in United States and Canada. Frequent co-authors include Jerome Santoro, Matthew E. Levison, P. G. Pitsakis, Elías Abrutyn, Lawrence L. Livornese, Robert L. Benz, Alexander F. Rosenberg, Audrey Wanger, B E Murray and D. Church. Their work appears in journals such as Infectious Disease Clinics of North America, The Journal of Infectious Diseases, Antimicrobial Agents and Chemotherapy and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.